Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Haemophilia

Volumn 22, Issue 4, 2016, Pages 514-520

  Valentino, L A ^a   Pipe, S W ^b   Collins, P W ^c   Blanchette, V S ^d   Berntorp, E ^e   Fischer, K ^f   Ewenstein, B M ^g   Oh, M ^g   Spotts, G ^g  

^a Baxalta US Inc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

bleeding; haemarthrosis; haemophilia; joint bleeding; pharmacokinetic guided treatment; prophylaxis; rAHF PFM

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLEEDING RISK; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK;

EID: 84979085792     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12905     Document Type: Article

References (26)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed November 4, 2007.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391–9.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
5. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700–10.
6. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359–67.
7. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119–27.
8. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; 77: 3–132.
9. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129–35.
10. Collins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269–75.
11. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689–97.
12. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl. 1): 101–8; discussion 9-10.
13. den Uijl IE, Mauser Bunschoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849–53.
14. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597–605.
15. Valentino LA. Considerations in individualizing prophylaxis in patients with hemophilia A. Haemophilia 2014; 20: 607–15.
16. Valentino LA, Reyes CM, Ewenstein B et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia 2014; 20: 630–8.
17. Hilbe JM. Negative Binomila Regression, 2nd edn. UK: Cambridge University Press, 2011.
18. Broderick CR, Herbert RD, Latimer J et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452–9.
19. Lindvall K, Astermark J, Bjorkman S et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855–9.
20. Aronstam A, Kirk PJ, McHardy J et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65–7.
21. Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004; 24: 414–26.
22. Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2011; 18: 8–16.
23. Khawaji M, Astermark J, Von Mackensen S, Åkesson K, Berntorp E. Bone density and health-related quality of life in adult patients with severe haemophilia. Haemophilia 2011; 17: 304–11.
24. Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219–27.
25. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment With rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119–27.
26. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.